ID   ARRB2_RAT               Reviewed;         410 AA.
AC   P29067;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   02-OCT-2024, entry version 183.
DE   RecName: Full=Beta-arrestin-2;
DE   AltName: Full=Arrestin beta-2;
GN   Name=Arrb2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=1517224; DOI=10.1016/s0021-9258(19)37125-x;
RA   Attramadal H., Arriza J.L., Aoki C., Dawson T.M., Codina J., Kwatra M.M.,
RA   Snyder S.H., Caron M.G., Lefkowitz R.J.;
RT   "Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene
RT   family.";
RL   J. Biol. Chem. 267:17882-17890(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 295-410.
RC   TISSUE=Pineal gland;
RX   PubMed=8308033; DOI=10.1016/s0021-9258(17)41820-5;
RA   Craft C.M., Whitmore D.H., Wiechmann A.F.;
RT   "Cone arrestin identified by targeting expression of a functional family.";
RL   J. Biol. Chem. 269:4613-4619(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 305-386.
RC   STRAIN=Sprague-Dawley; TISSUE=Retina;
RX   PubMed=9767391; DOI=10.1046/j.1460-9568.1998.t01-1-00271.x;
RA   Komori N., Cain S.D., Roch J.-M., Miller K.E., Matsumoto H.;
RT   "Differential expression of alternative splice variants of beta-arrestin-1
RT   and -2 in rat central nervous system and peripheral tissues.";
RL   Eur. J. Neurosci. 10:2607-2616(1998).
RN   [5]
RP   INTERACTION WITH IGF1R.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [6]
RP   FUNCTION IN INTERNALIZATION OF ADRB2, INTERACTION WITH CLTC AND AP2B1,
RP   MUTAGENESIS OF 374-LEU--PHE-377, AND SUBCELLULAR LOCATION.
RX   PubMed=10097102; DOI=10.1073/pnas.96.7.3712;
RA   Laporte S.A., Oakley R.H., Zhang J., Holt J.A., Ferguson S.S.G.,
RA   Caron M.G., Barak L.S.;
RT   "The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin
RT   adaptor AP-2 during endocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3712-3717(1999).
RN   [7]
RP   INTERACTION WITH SRC.
RX   PubMed=10753943; DOI=10.1074/jbc.275.15.11312;
RA   Miller W.E., Maudsley S., Ahn S., Khan K.D., Luttrell L.M., Lefkowitz R.J.;
RT   "beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase
RT   c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor
RT   endocytosis.";
RL   J. Biol. Chem. 275:11312-11319(2000).
RN   [8]
RP   FUNCTION IN INTERNALIZATION OF EDNRA AND EDNRB, AND MUTAGENESIS OF VAL-54.
RX   PubMed=10747877; DOI=10.1074/jbc.m000142200;
RA   Bremnes T., Paasche J.D., Mehlum A., Sandberg C., Bremnes B.,
RA   Attramadal H.;
RT   "Regulation and intracellular trafficking pathways of the endothelin
RT   receptors.";
RL   J. Biol. Chem. 275:17596-17604(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, INTERACTION WITH AP2B1 AND CLTC, AND MUTAGENESIS OF
RP   ARG-396 AND LYS-398.
RX   PubMed=10770944; DOI=10.1074/jbc.m002581200;
RA   Laporte S.A., Oakley R.H., Holt J.A., Barak L.S., Caron M.G.;
RT   "The interaction of beta-arrestin with the AP-2 adaptor is required for the
RT   clustering of beta 2-adrenergic receptor into clathrin-coated pits.";
RL   J. Biol. Chem. 275:23120-23126(2000).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10852825; DOI=10.1242/jcs.113.13.2463;
RA   Santini F., Penn R.B., Gagnon A.W., Benovic J.L., Keen J.H.;
RT   "Selective recruitment of arrestin-3 to clathrin coated pits upon
RT   stimulation of G protein-coupled receptors.";
RL   J. Cell Sci. 113:2463-2470(2000).
RN   [11]
RP   FUNCTION IN MAPK SIGNALING, AND INTERACTION WITH MAPK10; MAP2K4 AND MAP3K5.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E., Lin F.-T.,
RA   Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of
RT   JNK3.";
RL   Science 290:1574-1577(2000).
RN   [12]
RP   INTERACTION WITH CCR5.
RX   PubMed=11448957; DOI=10.1074/jbc.m102782200;
RA   Kraft K., Olbrich H., Majoul I., Mack M., Proudfoot A., Oppermann M.;
RT   "Characterization of sequence determinants within the carboxyl-terminal
RT   domain of chemokine receptor CCR5 that regulate signaling and receptor
RT   internalization.";
RL   J. Biol. Chem. 276:34408-34418(2001).
RN   [13]
RP   FUNCTION IN MAPK SIGNALING, AND INTERACTION WITH RAF1; MAP2K1 AND MAPK1.
RX   PubMed=11226259; DOI=10.1073/pnas.041604898;
RA   Luttrell L.M., Roudabush F.L., Choy E.W., Miller W.E., Field M.E.,
RA   Pierce K.L., Lefkowitz R.J.;
RT   "Activation and targeting of extracellular signal-regulated kinases by
RT   beta-arrestin scaffolds.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2449-2454(2001).
RN   [14]
RP   UBIQUITINATION, AND INTERACTION WITH MDM2.
RX   PubMed=11588219; DOI=10.1126/science.1063866;
RA   Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J.;
RT   "Regulation of receptor fate by ubiquitination of activated beta 2-
RT   adrenergic receptor and beta-arrestin.";
RL   Science 294:1307-1313(2001).
RN   [15]
RP   PHOSPHORYLATION AT SER-361 AND THR-383, INTERACTION WITH CLTC, AND
RP   MUTAGENESIS OF SER-361 AND THR-383.
RX   PubMed=12186555; DOI=10.1021/bi025705n;
RA   Lin F.-T., Chen W., Shenoy S., Cong M., Exum S.T., Lefkowitz R.J.;
RT   "Phosphorylation of beta-arrestin2 regulates its function in
RT   internalization of beta(2)-adrenergic receptors.";
RL   Biochemistry 41:10692-10699(2002).
RN   [16]
RP   INTERACTION WITH AP2B1.
RX   PubMed=11777907; DOI=10.1074/jbc.m108490200;
RA   Laporte S.A., Miller W.E., Kim K.-M., Caron M.G.;
RT   "beta-Arrestin/AP-2 interaction in G protein-coupled receptor
RT   internalization: identification of a beta-arrestin binding site in beta 2-
RT   adaptin.";
RL   J. Biol. Chem. 277:9247-9254(2002).
RN   [17]
RP   FUNCTION IN ERK SIGNALING.
RX   PubMed=11777902; DOI=10.1074/jbc.m106457200;
RA   Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., Luttrell L.M.;
RT   "beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK
RT   activity but inhibits ERK-mediated transcription following angiotensin AT1a
RT   receptor stimulation.";
RL   J. Biol. Chem. 277:9429-9436(2002).
RN   [18]
RP   FUNCTION IN INTERNALIZATION OF C5AR1, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH C5AR1.
RX   PubMed=12464600; DOI=10.1074/jbc.m210120200;
RA   Braun L., Christophe T., Boulay F.;
RT   "Phosphorylation of key serine residues is required for internalization of
RT   the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin,
RT   dynamin, and clathrin-dependent pathway.";
RL   J. Biol. Chem. 278:4277-4285(2003).
RN   [19]
RP   INTERACTION WITH LDLR.
RX   PubMed=12944399; DOI=10.1074/jbc.m309450200;
RA   Wu J.-H., Peppel K., Nelson C.D., Lin F.-T., Kohout T.A., Miller W.E.,
RA   Exum S.T., Freedman N.J.;
RT   "The adaptor protein beta-arrestin2 enhances endocytosis of the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 278:44238-44245(2003).
RN   [20]
RP   INTERACTION WITH PDE4D.
RX   PubMed=14500724; DOI=10.1074/jbc.m303772200;
RA   Bolger G.B., McCahill A., Huston E., Cheung Y.F., McSorley T.,
RA   Baillie G.S., Houslay M.D.;
RT   "The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase
RT   isoform confers preferential interaction with beta-arrestins.";
RL   J. Biol. Chem. 278:49230-49238(2003).
RN   [21]
RP   INTERACTION WITH CHUK; IKBKB AND MAP3K14.
RX   PubMed=15173580; DOI=10.1073/pnas.0402851101;
RA   Witherow D.S., Garrison T.R., Miller W.E., Lefkowitz R.J.;
RT   "beta-Arrestin inhibits NF-kappaB activity by means of its interaction with
RT   the NF-kappaB inhibitor IkappaBalpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8603-8607(2004).
RN   [22]
RP   INTERACTION WITH SMO.
RX   PubMed=15618519; DOI=10.1126/science.1104135;
RA   Chen W., Ren X.R., Nelson C.D., Barak L.S., Chen J.K., Beachy P.A.,
RA   de Sauvage F., Lefkowitz R.J.;
RT   "Activity-dependent internalization of smoothened mediated by beta-arrestin
RT   2 and GRK2.";
RL   Science 306:2257-2260(2004).
RN   [23]
RP   INTERACTION WITH AKT1; GSK3A AND GSK3B.
RX   PubMed=16051150; DOI=10.1016/j.cell.2005.05.012;
RA   Beaulieu J.-M., Sotnikova T.D., Marion S., Lefkowitz R.J.,
RA   Gainetdinov R.R., Caron M.G.;
RT   "An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic
RT   neurotransmission and behavior.";
RL   Cell 122:261-273(2005).
RN   [24]
RP   UBIQUITINATION, AND MUTAGENESIS OF 11-LYS-LYS-12.
RX   PubMed=15699045; DOI=10.1074/jbc.m412418200;
RA   Shenoy S.K., Lefkowitz R.J.;
RT   "Receptor-specific ubiquitination of beta-arrestin directs assembly and
RT   targeting of seven-transmembrane receptor signalosomes.";
RL   J. Biol. Chem. 280:15315-15324(2005).
RN   [25]
RP   FUNCTION IN UBIQUITINATION OF IGF1R.
RX   PubMed=15878855; DOI=10.1074/jbc.m501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of the
RT   insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3
RT   ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [26]
RP   INTERACTION WITH PDE4A.
RX   PubMed=15738310; DOI=10.1124/mol.104.009423;
RA   Wallace D.A., Johnston L.A., Huston E., Macmaster D., Houslay T.M.,
RA   Cheung Y.-F., Campbell L., Millen J.E., Smith R.A., Gall I., Knowles R.G.,
RA   Sullivan M., Houslay M.D.;
RT   "Identification and characterization of PDE4A11, a novel, widely expressed
RT   long isoform encoded by the human PDE4A cAMP phosphodiesterase gene.";
RL   Mol. Pharmacol. 67:1920-1934(2005).
RN   [27]
RP   UBIQUITINATION.
RX   PubMed=17666399; DOI=10.1074/jbc.m700852200;
RA   Shenoy S.K., Barak L.S., Xiao K., Ahn S., Berthouze M., Shukla A.K.,
RA   Luttrell L.M., Lefkowitz R.J.;
RT   "Ubiquitination of beta-arrestin links seven-transmembrane receptor
RT   endocytosis and ERK activation.";
RL   J. Biol. Chem. 282:29549-29562(2007).
RN   [28]
RP   FUNCTION IN DESENSITIZATION OF AGTR1, AND FUNCTION IN AGTR1-MEDIATED ERK
RP   SIGNALING.
RX   PubMed=18006496; DOI=10.1074/jbc.m706892200;
RA   Lee M.-H., El-Shewy H.M., Luttrell D.K., Luttrell L.M.;
RT   "Role of beta-arrestin-mediated desensitization and signaling in the
RT   control of angiotensin AT1a receptor-stimulated transcription.";
RL   J. Biol. Chem. 283:2088-2097(2008).
RN   [29]
RP   FUNCTION IN MAPK SIGNALING, INTERACTION WITH MAPK10 AND MAP3K5, AND
RP   MUTAGENESIS OF SER-198.
RX   PubMed=18408005; DOI=10.1074/jbc.m710006200;
RA   Guo C., Whitmarsh A.J.;
RT   "The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3
RT   activation by binding to its nonconserved N terminus.";
RL   J. Biol. Chem. 283:15903-15911(2008).
RN   [30]
RP   FUNCTION IN INTERNALIZATION OF CHRM1 AND CHRM2, AND MUTAGENESIS OF LYS-18;
RP   LYS-107; LYS-108; LYS-207 AND LYS-296.
RX   PubMed=19055777; DOI=10.1186/1750-2187-3-20;
RA   Mosser V.A., Jones K.T., Hoffman K.M., McCarty N.A., Jackson D.A.;
RT   "Differential role of beta-arrestin ubiquitination in agonist-promoted
RT   down-regulation of M1 vs M2 muscarinic acetylcholine receptors.";
RL   J. Mol. Signal. 3:20-20(2008).
RN   [31]
RP   INTERACTION WITH ARRDC1.
RX   PubMed=23886940; DOI=10.1242/jcs.130500;
RA   Puca L., Chastagner P., Meas-Yedid V., Israel A., Brou C.;
RT   "Alpha-arrestin 1 (ARRDC1) and beta-arrestins cooperate to mediate Notch
RT   degradation in mammals.";
RL   J. Cell Sci. 126:4457-4468(2013).
CC   -!- FUNCTION: Functions in regulating agonist-mediated G-protein coupled
CC       receptor (GPCR) signaling by mediating both receptor desensitization
CC       and resensitization processes. During homologous desensitization, beta-
CC       arrestins bind to the GPRK-phosphorylated receptor and sterically
CC       preclude its coupling to the cognate G-protein; the binding appears to
CC       require additional receptor determinants exposed only in the active
CC       receptor conformation. The beta-arrestins target many receptors for
CC       internalization by acting as endocytic adapters (CLASPs, clathrin-
CC       associated sorting proteins) and recruiting the GPRCs to the adapter
CC       protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the
CC       extent of beta-arrestin involvement appears to vary significantly
CC       depending on the receptor, agonist and cell type. Internalized
CC       arrestin-receptor complexes traffic to intracellular endosomes, where
CC       they remain uncoupled from G-proteins. Two different modes of arrestin-
CC       mediated internalization occur. Class A receptors, like ADRB2, OPRM1,
CC       ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the
CC       plasma membrane and undergo rapid recycling. Class B receptors, like
CC       AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with
CC       arrestin and traffic with it to endosomal vesicles, presumably as
CC       desensitized receptors, for extended periods of time. Receptor
CC       resensitization then requires that receptor-bound arrestin is removed
CC       so that the receptor can be dephosphorylated and returned to the plasma
CC       membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but
CC       not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and
CC       P2RY11 and ATP-stimulated internalization of P2RY2. Involved in
CC       phosphorylation-dependent internalization of OPRD1 and subsequent
CC       recycling or degradation. Involved in ubiquitination of IGF1R. Beta-
CC       arrestins function as multivalent adapter proteins that can switch the
CC       GPCR from a G-protein signaling mode that transmits short-lived signals
CC       from the plasma membrane via small molecule second messengers and ion
CC       channels to a beta-arrestin signaling mode that transmits a distinct
CC       set of signals that are initiated as the receptor internalizes and
CC       transits the intracellular compartment. Acts as a signaling scaffold
CC       for MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2
CC       and JNK3 activated by the beta-arrestin scaffold are largely excluded
CC       from the nucleus and confined to cytoplasmic locations such as
CC       endocytic vesicles, also called beta-arrestin signalosomes. Acts as a
CC       signaling scaffold for the AKT1 pathway. GPCRs for which the beta-
CC       arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent
CC       regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-
CC       arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is
CC       inhibited by the other respective beta-arrestin form (reciprocal
CC       regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated
CC       activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2
CC       signaling involving ligand CCL19. Is involved in type-1A angiotensin II
CC       receptor/AGTR1-mediated ERK activity. Is involved in type-1A
CC       angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in
CC       dopamine-stimulated AKT1 activity in the striatum by disrupting the
CC       association of AKT1 with its negative regulator PP2A. Involved in
CC       AGTR1-mediated chemotaxis. Appears to function as signaling scaffold
CC       involved in regulation of MIP-1-beta-stimulated CCR5-dependent
CC       chemotaxis. Involved in attenuation of NF-kappa-B-dependent
CC       transcription in response to GPCR or cytokine stimulation by
CC       interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-
CC       B-dependent activation by interacting with CHUK. The function is
CC       promoted by stimulation of ADRB2 and dephosphorylation of ARRB2.
CC       Involved in IL8-mediated granule release in neutrophils (By
CC       similarity). Involved in p53/TP53-mediated apoptosis by regulating MDM2
CC       and reducing the MDM2-mediated degradation of p53/TP53. May serve as
CC       nuclear messenger for GPCRs. Upon stimulation of OR1D2, may be involved
CC       in regulation of gene expression during the early processes of
CC       fertilization. Also involved in regulation of receptors other than
CC       GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates
CC       TGF-beta signaling such as NF-kappa-B activation. Involved in
CC       endocytosis of low-density lipoprotein receptor/LDLR. Involved in
CC       endocytosis of smoothened homolog/Smo, which also requires GRK2.
CC       Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and
CC       subsequent TGF-beta-mediated ERK activation and migration of epithelial
CC       cells. Involved in Toll-like receptor and IL-1 receptor signaling
CC       through the interaction with TRAF6 which prevents TRAF6
CC       autoubiquitination and oligomerization required for activation of NF-
CC       kappa-B and JUN. Involved in insulin resistance by acting as insulin-
CC       induced signaling scaffold for SRC, AKT1 and INSR. Involved in
CC       regulation of inhibitory signaling of natural killer cells by
CC       recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in the internalization
CC       of the atypical chemokine receptor ACKR3 (By similarity). Acts as an
CC       adapter protein coupling FFAR4 receptor to specific downstream
CC       signaling pathways, as well as mediating receptor endocytosis. During
CC       the activation step of NLRP3 inflammasome, directly associates with
CC       NLRP3 leading to inhibition of pro-inflammatory cytokine release and
CC       inhibition of inflammation. {ECO:0000250, ECO:0000250|UniProtKB:P32121,
CC       ECO:0000269|PubMed:10097102, ECO:0000269|PubMed:10747877,
CC       ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:11226259,
CC       ECO:0000269|PubMed:11777902, ECO:0000269|PubMed:12464600,
CC       ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:18006496,
CC       ECO:0000269|PubMed:18408005, ECO:0000269|PubMed:19055777}.
CC   -!- SUBUNIT: Homooligomer; the self-association is mediated by InsP6-
CC       binding (Probable). Heterooligomer with ARRB1; the association is
CC       mediated by InsP6-binding. Interacts with ADRB2 and CHRM2. Interacts
CC       with PDE4A. Interacts with PDE4D. Interacts with MAPK10, MAPK1 and
CC       MAPK3. Interacts with DRD2. Interacts with FSHR. Interacts with CLTC.
CC       Interacts with HTR2C. Interacts with CCR5. Interacts with CXCR4.
CC       Interacts with SRC. Interacts with DUSP16; the interaction is
CC       interrupted by stimulation of AGTR1 and activation of MAPK10. Interacts
CC       with CHUK; the interaction is enhanced stimulation of ADRB2. Interacts
CC       with RELA. Interacts with MDM2; the interaction is enhanced by
CC       activation of GPCRs. Interacts with SLC9A5. Interacts with TRAF6.
CC       Interacts with IGF1R. Interacts with ENG. Interacts with KIR2DL1,
CC       KIR2DL3 and KIR2DL4. Interacts with LDLR. Interacts with AP2B1.
CC       Interacts with C5AR1. Interacts with RAF1. Interacts with MAP2K1.
CC       Interacts with MAPK1. Interacts with MAPK10; the interaction enhances
CC       MAPK10 activation by MAP3K5. Interacts with MAP2K4; the interaction is
CC       enhanced by presence of MAP3K5 and MAPK10. Interacts with MAP3K5.
CC       Interacts with AKT1. Interacts with IKBKB and MAP3K14. Interacts with
CC       SMO (activated). Interacts with GSK3A and GSK3B. Associates with
CC       protein phosphatase 2A (PP2A). Interacts with CXCR4; the interaction is
CC       dependent on C-terminal phosphorylation of CXCR4 and allows activation
CC       of MAPK1 and MAPK3. Interacts with GPR143. Interacts with HCK and CXCR1
CC       (phosphorylated) (By similarity). Interacts with ACKR3 and ACKR4 (By
CC       similarity). Interacts with ARRDC1; the interaction is direct
CC       (PubMed:23886940). Interacts with GPR61, GPR62 and GPR135 (By
CC       similarity). Interacts (via NACHT and LRR domains) with NLRP3; this
CC       interaction is direct and inducible by omega-3 polyunsaturated fatty
CC       acids (PUFAs) (By similarity). Interacts with FFAR4 (via C-terminus);
CC       this interaction is stimulated by long-chain fatty acids (LCFAs) (By
CC       similarity). Interacts with GPR35 (By similarity). Interacts with GPR84
CC       (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P32121,
CC       ECO:0000269|PubMed:23886940, ECO:0000305}.
CC   -!- INTERACTION:
CC       P29067; P29067: Arrb2; NbExp=3; IntAct=EBI-1636616, EBI-1636616;
CC       P29067; P31749: AKT1; Xeno; NbExp=2; IntAct=EBI-1636616, EBI-296087;
CC       P29067; P53667: LIMK1; Xeno; NbExp=2; IntAct=EBI-1636616, EBI-444403;
CC       P29067; Q00987: MDM2; Xeno; NbExp=4; IntAct=EBI-1636616, EBI-389668;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000250}. Cell membrane.
CC       Membrane, clathrin-coated pit. Cytoplasmic vesicle {ECO:0000250}.
CC       Note=Translocates to the plasma membrane and colocalizes with
CC       antagonist-stimulated GPCRs.
CC   -!- TISSUE SPECIFICITY: Predominantly localized in neuronal tissues and in
CC       the spleen.
CC   -!- PTM: Phosphorylated at Thr-383 in the cytoplasm; probably
CC       dephosphorylated at the plasma membrane. The phosphorylation does not
CC       regulate internalization and recycling of ADRB2, interaction with
CC       clathrin or AP2B1 (By similarity). {ECO:0000250}.
CC   -!- PTM: The ubiquitination status appears to regulate the formation and
CC       trafficking of beta-arrestin-GPCR complexes and signaling.
CC       Ubiquitination appears to occur GPCR-specific. Ubiquitinated by MDM2;
CC       the ubiquitination is required for rapid internalization of ADRB2.
CC       Deubiquitinated by USP33; the deubiquitination leads to a dissociation
CC       of the beta-arrestin-GPCR complex. Stimulation of a class A GPCR, such
CC       as ADRB2, induces transient ubiquitination and subsequently promotes
CC       association with USP33. Stimulation of a class B GPCR promotes a
CC       sustained ubiquitination. Deubiquitinated by USP20; allowing USP20 to
CC       deubiquitinate TRAF6 leading to inhibition of NF-kappa-B signaling (By
CC       similarity). {ECO:0000250|UniProtKB:P32121}.
CC   -!- PTM: Hydroxylation by PHD2 modulates the rate of internalization by
CC       slowing down recruitment to the plasma membrane and inhibiting
CC       subsequent co-internalization with class A receptors. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the arrestin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M91590; AAA74460.1; -; mRNA.
DR   EMBL; BC087578; AAH87578.1; -; mRNA.
DR   EMBL; U03627; AAA17551.1; -; mRNA.
DR   EMBL; AF051457; AAC28617.1; -; Genomic_DNA.
DR   PIR; A59279; A59279.
DR   RefSeq; NP_037043.1; NM_012911.1.
DR   PDB; 6K3F; X-ray; 2.30 A; A/B/C/D/E/F=1-356.
DR   PDB; 8J9K; EM; 3.50 A; C=6-398.
DR   PDBsum; 6K3F; -.
DR   PDBsum; 8J9K; -.
DR   AlphaFoldDB; P29067; -.
DR   EMDB; EMD-36110; -.
DR   SMR; P29067; -.
DR   BioGRID; 247426; 12.
DR   CORUM; P29067; -.
DR   DIP; DIP-40507N; -.
DR   IntAct; P29067; 21.
DR   MINT; P29067; -.
DR   STRING; 10116.ENSRNOP00000026207; -.
DR   iPTMnet; P29067; -.
DR   PhosphoSitePlus; P29067; -.
DR   PaxDb; 10116-ENSRNOP00000026207; -.
DR   GeneID; 25388; -.
DR   KEGG; rno:25388; -.
DR   UCSC; RGD:2157; rat.
DR   AGR; RGD:2157; -.
DR   CTD; 409; -.
DR   RGD; 2157; Arrb2.
DR   VEuPathDB; HostDB:ENSRNOG00000019308; -.
DR   eggNOG; KOG3865; Eukaryota.
DR   HOGENOM; CLU_033484_1_1_1; -.
DR   InParanoid; P29067; -.
DR   OrthoDB; 3059077at2759; -.
DR   PhylomeDB; P29067; -.
DR   Reactome; R-RNO-418555; G alpha (s) signalling events.
DR   Reactome; R-RNO-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-RNO-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-RNO-5674135; MAP2K and MAPK activation.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-RNO-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-RNO-9839389; TGFBR3 regulates TGF-beta signaling.
DR   PRO; PR:P29067; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000019308; Expressed in thymus and 19 other cell types or tissues.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:RGD.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0030139; C:endocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:ARUK-UCL.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:SynGO.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:RGD.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:RGD.
DR   GO; GO:0031691; F:alpha-1A adrenergic receptor binding; IPI:RGD.
DR   GO; GO:0031692; F:alpha-1B adrenergic receptor binding; IDA:RGD.
DR   GO; GO:0031701; F:angiotensin receptor binding; ISO:RGD.
DR   GO; GO:1990763; F:arrestin family protein binding; IPI:UniProtKB.
DR   GO; GO:0031748; F:D1 dopamine receptor binding; IPI:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0031762; F:follicle-stimulating hormone receptor binding; IPI:RGD.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:RGD.
DR   GO; GO:0060090; F:molecular adaptor activity; ISO:RGD.
DR   GO; GO:0031859; F:platelet activating factor receptor binding; IPI:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0043422; F:protein kinase B binding; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IPI:RGD.
DR   GO; GO:0031826; F:type 2A serotonin receptor binding; IPI:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0007628; P:adult walking behavior; ISO:RGD.
DR   GO; GO:0060326; P:cell chemotaxis; ISO:RGD.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IMP:RGD.
DR   GO; GO:0006897; P:endocytosis; IDA:RGD.
DR   GO; GO:0042699; P:follicle-stimulating hormone signaling pathway; IDA:RGD.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; ISO:RGD.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; ISO:RGD.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0045953; P:negative regulation of natural killer cell mediated cytotoxicity; ISO:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:2000475; P:negative regulation of opioid receptor signaling pathway; IDA:RGD.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:RGD.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IMP:RGD.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IMP:RGD.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; ISO:RGD.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IMP:RGD.
DR   GO; GO:2000727; P:positive regulation of cardiac muscle cell differentiation; ISO:RGD.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IMP:RGD.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:RGD.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IMP:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:RGD.
DR   GO; GO:2000476; P:positive regulation of opioid receptor signaling pathway; IMP:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:RGD.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IMP:RGD.
DR   GO; GO:0032226; P:positive regulation of synaptic transmission, dopaminergic; ISO:RGD.
DR   GO; GO:0098926; P:postsynaptic signal transduction; ISO:RGD.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISO:RGD.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0016567; P:protein ubiquitination; ISO:RGD.
DR   GO; GO:0031623; P:receptor internalization; ISO:RGD.
DR   GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0043278; P:response to morphine; IEP:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   Gene3D; 2.60.40.640; -; 1.
DR   Gene3D; 2.60.40.840; -; 1.
DR   InterPro; IPR000698; Arrestin.
DR   InterPro; IPR014752; Arrestin-like_C.
DR   InterPro; IPR011021; Arrestin-like_N.
DR   InterPro; IPR011022; Arrestin_C-like.
DR   InterPro; IPR017864; Arrestin_CS.
DR   InterPro; IPR014753; Arrestin_N.
DR   InterPro; IPR014756; Ig_E-set.
DR   PANTHER; PTHR11792; ARRESTIN; 1.
DR   PANTHER; PTHR11792:SF20; BETA-ARRESTIN-2; 1.
DR   Pfam; PF02752; Arrestin_C; 1.
DR   Pfam; PF00339; Arrestin_N; 1.
DR   PRINTS; PR00309; ARRESTIN.
DR   SMART; SM01017; Arrestin_C; 1.
DR   SUPFAM; SSF81296; E set domains; 2.
DR   PROSITE; PS00295; ARRESTINS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Coated pit; Cytoplasm; Cytoplasmic vesicle;
KW   Hydroxylation; Membrane; Nucleus; Phosphoprotein; Protein transport;
KW   Reference proteome; Signal transduction inhibitor; Transport;
KW   Ubl conjugation.
FT   CHAIN           1..410
FT                   /note="Beta-arrestin-2"
FT                   /id="PRO_0000205201"
FT   REGION          241..410
FT                   /note="Interaction with TRAF6"
FT                   /evidence="ECO:0000250"
FT   REGION          378..410
FT                   /note="Interaction with AP2B1"
FT   MOTIF           386..396
FT                   /note="[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         48
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91YI4"
FT   MOD_RES         176
FT                   /note="Hydroxyproline; by PHD2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         181
FT                   /note="Hydroxyproline; by PHD2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         361
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12186555"
FT   MOD_RES         383
FT                   /note="Phosphothreonine; by CaMK2"
FT                   /evidence="ECO:0000305|PubMed:12186555"
FT   MUTAGEN         11..12
FT                   /note="KK->RR: Transient ubiquitination; no stable
FT                   endocytic complexes with AGTR1; impaired in scaffolding-
FT                   activated ERK1/2."
FT                   /evidence="ECO:0000269|PubMed:15699045"
FT   MUTAGEN         18
FT                   /note="K->R: Promotes agonist-stimulated down-regulation of
FT                   CHRM2 and CHRM1; no effect on internalization of CHRM2;
FT                   when associated with R-107, R-108, R-207 and R-296."
FT                   /evidence="ECO:0000269|PubMed:19055777"
FT   MUTAGEN         54
FT                   /note="V->A: Inhibits internalization of EDNRA and EDNRB."
FT                   /evidence="ECO:0000269|PubMed:10747877"
FT   MUTAGEN         107
FT                   /note="K->R: Promotes agonist-stimulated down-regulation of
FT                   CHRM2 and CHRM1; no effect on internalization of CHRM2;
FT                   when associated with R-18, R-108, R-207 and R-296."
FT                   /evidence="ECO:0000269|PubMed:19055777"
FT   MUTAGEN         108
FT                   /note="K->R: Promotes agonist-stimulated down-regulation of
FT                   CHRM2 and CHRM1; no effect on internalization of CHRM2;
FT                   when associated with R-18, R-107, R-207 and R-296."
FT                   /evidence="ECO:0000269|PubMed:19055777"
FT   MUTAGEN         198
FT                   /note="S->P: Greatly reduces interaction with MAPK10."
FT                   /evidence="ECO:0000269|PubMed:18408005"
FT   MUTAGEN         207
FT                   /note="K->R: Promotes agonist-stimulated down-regulation of
FT                   CHRM2 and CHRM1; no effect on internalization of CHRM2;
FT                   when associated with R-18, R-107, R-108 and R-296."
FT                   /evidence="ECO:0000269|PubMed:19055777"
FT   MUTAGEN         296
FT                   /note="K->R: Promotes agonist-stimulated down-regulation of
FT                   CHRM2 and CHRM1; no effect on internalization of CHRM2;
FT                   when associated with R-18, R-107, R-108 and R-207."
FT                   /evidence="ECO:0000269|PubMed:19055777"
FT   MUTAGEN         361
FT                   /note="S->D: Almost abolishes phosphorylation; inhibits
FT                   internalization of ADRB2; when associated with D-383."
FT                   /evidence="ECO:0000269|PubMed:12186555"
FT   MUTAGEN         361
FT                   /note="S->D: Reduces interaction with CLTC."
FT                   /evidence="ECO:0000269|PubMed:12186555"
FT   MUTAGEN         374..377
FT                   /note="LIEF->AAEA: Abolishes interaction with CLTC; reduces
FT                   interaction with AP2B1."
FT                   /evidence="ECO:0000269|PubMed:10097102"
FT   MUTAGEN         383
FT                   /note="T->D: Almost abolishes phosphorylation; inhibits
FT                   internalization of ADRB2; when associated with D-361."
FT                   /evidence="ECO:0000269|PubMed:12186555"
FT   MUTAGEN         383
FT                   /note="T->D: Reduces interaction with CLTC."
FT                   /evidence="ECO:0000269|PubMed:12186555"
FT   MUTAGEN         394
FT                   /note="R->A: Abolishes interaction with AP2B1; no effect on
FT                   interaction with clathrin."
FT   MUTAGEN         396
FT                   /note="R->A: Abolishes interaction with AP2B1."
FT                   /evidence="ECO:0000269|PubMed:10770944"
FT   MUTAGEN         398
FT                   /note="K->A: No effect on interaction with AP2B1."
FT                   /evidence="ECO:0000269|PubMed:10770944"
FT   STRAND          10..13
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          17..24
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          26..30
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          32..34
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          41..44
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   TURN            46..48
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          55..63
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   TURN            67..71
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          80..85
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   HELIX           100..108
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          129..131
FT                   /evidence="ECO:0007829|PDB:8J9K"
FT   STRAND          142..150
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          168..173
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          185..187
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          200..204
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          216..223
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          230..240
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          243..251
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          253..260
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          266..269
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          272..276
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   TURN            280..282
FT                   /evidence="ECO:0007829|PDB:8J9K"
FT   STRAND          283..285
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          289..293
FT                   /evidence="ECO:0007829|PDB:8J9K"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:8J9K"
FT   STRAND          314..317
FT                   /evidence="ECO:0007829|PDB:8J9K"
FT   STRAND          325..331
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   TURN            332..334
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          335..339
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          343..345
FT                   /evidence="ECO:0007829|PDB:6K3F"
FT   STRAND          387..391
FT                   /evidence="ECO:0007829|PDB:8J9K"
SQ   SEQUENCE   410 AA;  46340 MW;  0DFA6A897C2B86BA CRC64;
     MGEKPGTRVF KKSSPNCKLT VYLGKRDFVD HLDKVDPVDG VVLVDPDYLK DRKVFVTLTC
     AFRYGREDLD VLGLSFRKDL FIATYQAFPP MPNPPRPPTR LQDRLLKKLG QHAHPFFFTI
     PQNLPCSVTL QPGPEDTGKA CGVDFEIRAF CAKSIEEKSH KRNSVRLIIR KVQFAPETPG
     PQPSAETTRH FLMSDRRSLH LEASLDKELY YHGEPLNVNV HVTNNSAKTV KKIRVSVRQY
     ADICLFSTAQ YKCPVAQLEQ DDQVSPSSTF CKVYTITPLL SDNREKRGLA LDGQLKHEDT
     NLASSTIVKE GANKEVLGIL VSYRVKVKLV VSRGGDVSVE LPFVLMHPKP HDHITLPRPQ
     SAPREIDIPV DTNLIEFDTN YATDDDIVFE DFARLRLKGM KDDDCDDQFC
//
